Categories
Change Password!
Reset Password!
The safety and effectiveness of integrating the 308-nm Excimer lamp with Tacrolimus 0.1% ointment was examined in comparison to using Tacrolimus 0.1% ointment alone for tackling vitiligo in kids.
Pediatric vitiligo patients treated with Tacrolimus in conjunction with the 308-nm excimer lamp show better repigmentation outcomes than those treated solely with Tacrolimus.
The safety and effectiveness of integrating the 308-nm Excimer lamp with Tacrolimus 0.1% ointment was examined in comparison to using Tacrolimus 0.1% ointment alone for tackling vitiligo in kids.
Overall, 50 vitiligo (affecting <10% of the body surface area) pediatrics were randomly segregated into two groups. Group A was given Tacrolimus 0.1% ointment twice daily along with 308-nm Excimer light treatment twice weekly. Contrarily, Group B was managed solely with Tacrolimus 0.1% ointment twice daily. At 30, 90, and 180 days, repigmentation percentages were assessed utilizing the rule of nine.
Group A demonstrated remarkable improvement in repigmentation, escalating from 10% at one month to 65% at six months. Conversely, Group B experienced a rise from 10% to 30% during a similar period. Group A exhibited considerably higher therapeutic efficiency at both the 3-month and 6-month follow-up intervals (p-value < .001). Furthermore, Group A attained notably superior repigmentation rates in the lower limb, trunk, and facial areas. Minimal side effects were observed,
In pediatrics suffering from vitiligo, combining Tacrolimus (calcineurin inhibitor) with the 308-nm excimer lamp led to better repigmentation outcomes as opposed to Tacrolimus monotherapy. This combined therapeutic approach may present a promising and safe novel treatment regimen for pediatric vitiligo.
Journal of Dermatological Treatment
Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial
Diala Alshiyab et al.
Comments (0)